The global demand for Artificial Intelligence (AI) in Drug Discovery Market is presumed to reach the market size of nearly USD 27.25 BN by 2030 from USD 1.19 BN in 2022 with a CAGR of 47.9% under the study period of 2023 - 2030.
Artificial intelligence (AI) in Drug Discovery is a technology that employs machines to simulate human intelligence to solve challenging issues in the drug discovery process. The technology helps in discovering novel compounds and aids in the identification of therapeutic targets and the development of tailored medications. The system has numerous applications, including deriving insights into identifying drugs and lessening the severity of various chronic diseases. This market includes AI for drug discovery sales and related services.
Some of the main drivers propelling the growth of AI in the drug delivery market include the rising usage of cloud-based applications and services and the impending patent expiration of blockbuster pharmaceuticals. Additional factors boosting demand are the growing need to control drug discovery costs and less time required for drug development. Further, the technology demand is also rising due to the discovery and development of novel pharmacological therapies and the expanding manufacturing capabilities of the life science industry. However, several problems are anticipated to impede the growth of this industry in the years to come, including a lack of skilled AI workers, hazy regulatory requirements for medical software, and a lack of data sets in this area. Nonetheless, the growing frequency of cross-industry partnerships will be a major driver influencing the market's development rate.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of artificial intelligence ( ai) in drug discovery. The growth and trends of Artificial Intelligence ( AI) in Drug Discovery Industry provide a holistic approach to this study.
This section of the artificial intelligence ( ai) in drug discovery market report provides detailed data on the segments by analyzing them at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
- Machine Learning
- Deep Learning
- Supervised Learning
- Reinforcement Learning
- Unsupervised Learning
- Other Machine Learning Technologies
- Other Technologies
- Neurodegenerative Diseases
- Cardiovascular Diseases
- Metabolic Diseases
- Other Applications
By End User
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Research Centers And Academic & Government Institutes
This section covers the regional outlook, which accentuates current and future demand for the Artificial Intelligence ( AI) in Drug Discovery market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Artificial Intelligence (AI) in Drug Discovery Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the artificial intelligence ( ai) in drug discovery market include Microsoft Corporation (US), Exscientia (UK), NVIDIA Corporation (US), Schrödinger (US), Atomwise, Inc. (US), BenevolentAI (UK), NuMedii (US), Google (US), Insilico Medicine (US), BERG LLC (US), Cloud Pharmaceuticals (US), Cyclica (Canada), Deep Genomics (Canada), IBM (US), BIOAGE (US), Valo Health (US), Envisagenics (US), twoXAR (US), XtalPi (US), Verge Genomics (US), Owkin, Inc. (US), Biovista (US), Evaxion Biotech (Denmark), Iktos (France), Standigm (South Korea), and BenchSci (Canada). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.